Key result
Sitagliptin shows no association with altered MACE risk in diabetics with recent ischemic stroke.
Why the study?
Does sitagliptin reduce the composite of ischemic stroke, myocardial infarction, or cardiovascular death in patients with type 2 diabetes mellitus and recent ischemic stroke?
Population
5,145 patients with type 2 diabetes mellitus (T2DM) and recent ischemic stroke
Comparison
Sitagliptin vs No sitagliptin
Design
Cohort
Follow-up
up to 2.83 years (mean, 1.17 years)
Authors
Loading...
Supports sitagliptin CV safety in T2DM with recent stroke; leaves open effects in broader populations pending RCTs.
Cohort (n=5,145)
Yes
Does sitagliptin reduce the composite of ischemic stroke, myocardial infarction, or cardiovascular death in patients with type 2 diabetes mellitus and recent ischemic stroke?
Hazard Ratio: 1.02 (95% CI 0.85–1.21)
Absolute Event Rate: 11.1% vs 10.8%
In patients with type 2 diabetes and recent ischemic stroke, sitagliptin use was neutral regarding cardiovascular and cerebrovascular outcomes.
Chen et al. (2015) conducted a cohort in Type 2 diabetes mellitus with recent ischemic stroke (n=5,145). Sitagliptin vs. No sitagliptin was evaluated on Composite of ischemic stroke, myocardial infarction, or cardiovascular death (HR 1.02, 95% CI 0.85-1.21). Sitagliptin use in type 2 diabetic patients with recent ischemic stroke was not associated with an altered risk of ischemic stroke, MI, or cardiovascular death (HR 1.02; 95% CI 0.85-1.21).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: